FORMAL PROTEST OF PENTERRA PHARMACEUTICALS CORP.
Filed in Response to the Notice of Proposed Adjustment Dated October 12, 2023, and 30-Day Letter Dated November 8, 2023
IRS Examination Team ID: LB&I-NE-TP-2022-00641
Tax Years at Issue: 2017, 2018, 2019, 2020
Filed: December 22, 2023
Submitted by:
Calderwood & Harkness LLP, as authorized representatives of Penterra Pharmaceuticals Corp., pursuant to IRS Form 2848 filed June 8, 2022.
Addressed to:
Supervisory Revenue Agent Gerald Meskill Team Manager IRS Large Business & International Division Northeast Transfer Pricing Practice
Copies to:
Revenue Agent Patricia Dunleavy, Lead Revenue Agent Franklin Rosario, Attorney-Advisor, IRS Office of Chief Counsel
From:
Leonard Cross, Responsible Partner, Tax Department Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103
Sylvia Hartwell, Billing Partner, Tax Department Calderwood & Harkness LLP 600 Lexington Avenue New York, NY 10022
Right-click to update Table of Contents
I. INTRODUCTION AND REQUEST FOR APPEALS CONFERENCE
Penterra Pharmaceuticals Corp. ("PPC"), Employer Identification Number 22-3741856, a Delaware corporation publicly traded on the Nasdaq Stock Market under ticker symbol PPCA, hereby files this Formal Protest pursuant to the right granted by the 30-Day Letter dated November 8, 2023, the response deadline for which was extended by agreement of the parties to December 22, 2023. PPC's principal place of business and headquarters is located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. The tax returns at issue are PPC's U.S. federal income tax returns on Form 1120 for the taxable years ending December 31, 2017, December 31, 2018, December 31, 2019, and December 31, 2020 (collectively, the "Tax Years at Issue" or "TY 2017–2020"). PPC was not a participant in the IRS Compliance Assurance Process ("CAP") for any of the Tax Years at Issue.
PPC contests in full the proposed adjustments totaling $380,400,000 for Tax Years 2017, 2018, 2019, and 2020, as set forth in the Notice of Proposed Adjustment ("NOPA") dated October 12, 2023, issued by the IRS Large Business & International Division ("LB&I"), Northeast Transfer Pricing Practice, Examination Team ID LB&I-NE-TP-2022-00641. PPC also contests the proposed penalty under Internal Revenue Code ("IRC") § 6662(e) for substantial valuation misstatement in the amount of approximately $15,977,000. PPC submits that neither the proposed adjustments nor the proposed penalty have any basis in law or fact, and both should be withdrawn in their entirety.
PPC respectfully requests an Appeals conference pursuant to Revenue Procedure 2015-41 to resolve this matter at the earliest available date. PPC believes that a full and fair consideration of the factual record and applicable legal authority by the IRS Office of Appeals will demonstrate that PPC's transfer pricing arrangements with its Irish subsidiary, Penterra Biopharma International DAC ("PBI"), are fully arm's-length and in compliance with IRC § 482 and the applicable Treasury Regulations.
Calderwood & Harkness LLP represents PPC as authorized representatives pursuant to IRS Form 2848, Power of Attorney and Declaration of Representative, filed with the Internal Revenue Service on June 8, 2022. The authorized representatives designated on the Form 2848 are Leonard Cross, Sylvia Hartwell, Garrett Simmons, and Leila Nazari, each of whom is a duly admitted attorney and member in good standing of the bar of at least one state.
The adjustments proposed by the IRS fundamentally mischaracterize PPC's arm's-length transfer pricing arrangements with PBI under both cost-sharing and royalty arrangements that fully comply with IRC § 482 and the applicable Treasury Regulations. Specifically, the IRS proposes to (i) increase PBI's cost-sharing percentages under a qualified cost-sharing arrangement ("CSA") by 8 to 12 percentage points per year, (ii) increase the royalty rate on legacy intellectual property from 4.5% to 11.0% of net sales, and (iii) assert a substantial valuation misstatement penalty under IRC § 6662(e). As demonstrated below, each of these proposed adjustments is unsupported by reliable economic analysis, inconsistent with the regulatory framework governing cost-sharing arrangements and intangible property transfers, and contrary to the weight of applicable case law.
II. STATEMENT OF FACTS
A. Penterra Pharmaceuticals Corp. — Overview
PPC is a specialty pharmaceutical and biotechnology company focused on three principal therapeutic areas: oncology, immunology, and rare-disease therapeutics. The company was incorporated under the laws of the State of Delaware and maintains its corporate headquarters at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC's common stock is publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA.
PPC is led by a seasoned management team with deep experience in the global pharmaceutical industry. The company's Chief Executive Officer is Catherine Falk, who has served in that capacity since 2015. The Chief Financial Officer is Rajesh Iyer, who joined PPC in 2014. The General Counsel is Deborah Staines, and the Vice President, Global Tax is Marcus Whitfield. Mr. Whitfield has primary oversight responsibility for PPC's transfer pricing policies and intercompany arrangements, and has been intimately involved in the matters at issue in this Protest.
For its fiscal year ended December 31, 2020, PPC reported annual consolidated revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. PPC employs approximately 14,500 individuals globally, with operations spanning research and development, manufacturing, commercial, and administrative functions across the Americas, Europe, the Middle East and Africa ("EMEA"), and the Asia-Pacific region ("APAC").
PPC's product portfolio includes several significant therapeutic compounds, the most important of which for purposes of this Protest are the following:
• Veritaxol — PPC's flagship oncology product and a blockbuster compound. Veritaxol generated global net sales of approximately $3.12 billion in fiscal year 2020, of which approximately $1.34 billion (43%) was attributable to non-Americas territories (i.e., EMEA and APAC).
• Imvara — An immunology product with global net sales of approximately $1.87 billion in fiscal year 2020, of which approximately $0.79 billion (42%) was attributable to non-Americas territories.
• Cerulon — A rare-disease therapeutic with global net sales of approximately $0.62 billion in fiscal year 2020, of which approximately $0.28 billion (45%) was attributable to non-Americas territories.
These three products, together with additional pipeline compounds and legacy products, constitute the portfolio of pharmaceutical intellectual property at the center of the transfer pricing issues raised by the IRS in this examination.
B. Corporate Structure — Relevant Entities
The corporate structure relevant to this Protest involves four entities, organized in a tiered ownership chain as follows:
1. Penterra Pharmaceuticals Corp. ("PPC") — The ultimate parent company. Incorporated in Delaware; headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550; EIN 22-3741856.
2. Penterra Holdings Luxembourg S.à r.l. ("PHL") — A Luxembourg private limited liability company (société à responsabilité limitée), 100% owned by PPC. PHL is registered at 14, rue Aldringen, L-1118 Luxembourg, Luxembourg RCS No. B 168452. PHL is treated as a disregarded entity for U.S. federal income tax purposes and, accordingly, all of its assets, liabilities, income, and activities are attributed to PPC for U.S. tax purposes. PHL serves as an intermediate holding company in PPC's European corporate structure.
3. Penterra Biopharma International DAC ("PBI") — A Designated Activity Company organized under Irish law, 100% owned by PHL and thus indirectly 100% owned by PPC. PBI is registered at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI's Irish Tax Reference Number is 3218764T. PBI was incorporated on March 15, 2012, and commenced operations shortly thereafter. PBI is the entity at the center of this transfer pricing dispute, serving as the IP-holding company and commercial principal for PPC's non-Americas operations.
4. Penterra Manufacturing Ireland Ltd. ("PMI") — An Irish private limited company, 100% owned by PBI. PMI is registered at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland, CRO No. 512347. PMI serves as a contract manufacturer for PBI under a cost-plus arrangement (cost plus 8%), employing approximately 620 individuals at its Ringaskiddy manufacturing facility. PMI manufactures active pharmaceutical ingredients and finished dosage forms for distribution across non-Americas territories.
A diagram setting forth the corporate structure in greater detail is attached hereto as Exhibit A (Corporate Structure Chart).
C. PBI — Functions, Assets, and Risks
PBI serves as the intellectual property–holding company and commercial principal for the non-Americas (EMEA and APAC) commercialization of PPC's pharmaceutical products. PBI was established in 2012 as part of PPC's strategic initiative to centralize its non-Americas operations under a single, well-resourced entity with meaningful decision-making authority and operational capability. Since its inception, PBI has built significant operational infrastructure, human capital, and commercial capabilities.
PBI's Managing Director is Aidan Naughton, who has been based in Dublin, Ireland since PBI's incorporation. Mr. Naughton reports to PPC's Chief Executive Officer but exercises substantial independent authority over PBI's commercial and operational decisions. PBI's management team includes senior professionals in regulatory affairs, medical affairs, commercial strategy, supply-chain management, and distribution partner management.
PBI's employee base has grown substantially over the period since its establishment. At the time of its incorporation in March 2012, PBI employed 52 individuals. By fiscal year 2020, PBI's headcount had grown to 185 employees, all based in Ireland or assigned to PBI's operations in non-Americas territories. This growth trajectory reflects PBI's increasing operational responsibilities and its expanding role in the commercialization of PPC's product portfolio outside the Americas.
PBI's functional areas encompass the full range of activities necessary to commercialize pharmaceutical products in non-Americas markets:
• Regulatory Affairs: PBI maintains a dedicated regulatory affairs team responsible for obtaining and maintaining marketing authorizations across non-Americas markets. During the Tax Years at Issue (2017–2020), PBI expended a cumulative total of approximately €47.2 million on regulatory submissions, filings, and approvals across its territories. This includes submissions to the European Medicines Agency ("EMA"), national competent authorities across the European Union, and regulatory bodies in APAC jurisdictions including Japan's Pharmaceuticals and Medical Devices Agency ("PMDA"), Australia's Therapeutic Goods Administration ("TGA"), and other relevant authorities.
• Medical Affairs: PBI employs medical affairs professionals who engage with key opinion leaders, healthcare providers, and clinical investigators in non-Americas markets. These activities support product commercialization, post-marketing surveillance, and the development of scientific evidence to support regulatory and reimbursement submissions.
• Commercial Strategy: PBI's commercial strategy team is responsible for market access, pricing strategy, and go-to-market planning across 68 country markets in its territories. PBI made independent pricing decisions in each of these 68 markets, taking into account local competitive dynamics, payer landscapes, reimbursement environments, and regulatory constraints. These decisions were made by PBI's Dublin-based management team and were not directed by PPC's U.S. operations.
• Supply-Chain Management: PBI managed the supply chain for non-Americas territories, including oversight of its contract manufacturing subsidiary PMI and coordination with third-party logistics providers and distributors.
• Distribution Partner Management: PBI maintained relationships with third-party distributors in markets where it did not have direct sales operations, negotiating distribution agreements and managing commercial performance.
PBI maintained approximately 18,000 square feet of dedicated office space at Sandyford Business Park in Dublin, Ireland. This space housed PBI's management team and operational staff and served as the primary location for PBI's commercial and administrative activities.
During the Tax Years at Issue, PBI's board of directors held a total of 42 board meetings in Dublin, including quarterly meetings and special sessions. These board meetings were fully documented by formal minutes and addressed key commercial decisions including product launch strategies, pricing decisions, budget approvals, capital expenditure authorizations, and regulatory submission strategies. The board meetings were substantive in nature and reflected genuine decision-making by PBI's directors and management.
PBI maintained independent banking relationships with Glenmore Bank Ireland plc, through which it conducted its treasury operations, received revenue from customers, and made payments to suppliers, employees, and intercompany counterparties. PBI's financial operations were managed independently by its Dublin-based finance team.
PBI bore genuine and meaningful economic risks in connection with its non-Americas operations. These risks included: (i) pricing risk, arising from the need to set and adjust product prices across 68 country markets with varying competitive, regulatory, and reimbursement environments; (ii) regulatory approval risk, including the risk that regulatory submissions would be rejected, delayed, or conditioned upon additional clinical data or post-marketing commitments; (iii) commercial risk, including the risk that products would fail to achieve projected market share or revenue targets in non-Americas markets; and (iv) foreign exchange risk, arising from PBI's receipt of revenues and incurrence of costs in multiple currencies, including the euro, British pound, Japanese yen, Australian dollar, and other currencies.
For its fiscal year ended December 31, 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI claimed Ireland's Knowledge Development box ("KDB") rate of 6.25% on qualifying intellectual property income, available from fiscal year 2016 forward pursuant to Ireland's Finance Act 2015, in addition to the standard 12.5% Irish trading rate on non-qualifying trading income. PBI's Irish tax filings were prepared and filed in compliance with applicable Irish tax law and were consistent with the OECD's Base Erosion and Profit Shifting ("BEPS") framework, including the modified nexus approach adopted by Ireland in implementing the KDB regime.
D. The Cost-Sharing Arrangement
PPC and PBI entered into a qualified cost-sharing arrangement ("CSA") effective July 1, 2012, pursuant to Treasury Regulation § 1.482-7. The CSA was documented in a written agreement (the "CSA Agreement") that was executed contemporaneously with its effective date and has been maintained in PPC's files and produced to the IRS during the examination.
Under the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical intellectual property portfolio outside the Americas. For purposes of the CSA, "Americas" is defined to include North America, Central America, South America, and the Caribbean. PBI's territory under the CSA encompasses all markets outside the Americas, including EMEA and APAC.
As consideration for PBI's acquisition of rights to the pre-existing intellectual property contributed to the CSA by PPC, PBI made a platform contribution transaction ("PCT") payment of $312,000,000 to PPC on July 1, 2012. This PCT payment represented the buy-in to pre-existing IP, which at the time consisted primarily of clinical-stage and approved oncology compounds, including the early-stage assets that would ultimately be developed into Veritaxol, as well as certain immunology and rare-disease pipeline compounds. The valuation of the PCT payment is discussed in greater detail in Section IV.C below.
Under the ongoing cost-sharing provisions of the CSA, PPC and PBI share intangible development costs ("Coss") in proportion to their reasonably anticipated benefits ("RABs") from the exploitation of the intellectual property developed under the CSA. The RABs are measured by reference to projected revenue splits between the Americas and non-Americas territories, consistent with the requirements of Treasury Regulation § 1.482-7(e).
The cost-sharing ratios applicable to each of the Tax Years at Issue, together with the total qualified R&D costs and PBI's share of such costs, are set forth in the following table:
The gradual increase in PBI's cost-sharing percentage from 38.2% in 2017 to 42.7% in 2020 reflects the growing non-Americas share of projected revenues, which in turn reflects PBI's expanding commercial presence and market penetration in EMEA and APAC markets over the relevant period. The cost-sharing ratios were derived from detailed product-level revenue projections prepared contemporaneously with each tax year, and the methodology for calculating RABs was applied consistently throughout the period.
A summary of the CSA, including the cost-sharing ratios and supporting data, is attached hereto as Exhibit B (Summary of Cost-Sharing Arrangement).
E. The Legacy IP Royalty Arrangement
Separately from the CSA, PBI licensed certain legacy pharmaceutical compounds from PPC under an intercompany license agreement (the "Legacy IP License"). The Legacy IP License covers compounds that were of pre-2012 vintage and were not included within the scope of the CSA. These legacy compounds are mature products that were already on the market at the time PBI was established, and their non-Americas commercialization rights were licensed to PBI under arms'-length terms determined at the time the license was entered into.
Under the Legacy IP License, PBI pays PPC a royalty of 4.5% of net sales for the non-Americas territory. The royalty rate was established based on a comparability analysis conducted at the time the license was entered into and has remained unchanged throughout the Tax Years at Issue.
The following table sets forth the non-Americas net sales of legacy compounds and the corresponding royalty payments made by PBI to PPC for each of the Tax Years at Issue:
As reflected in the table above, legacy compound net sales in the non-Americas territory declined steadily over the four-year period from $814.6 million in 2017 to $624.1 million in 2020. This declining sales trajectory is entirely consistent with the mature product lifecycle of these compounds, many of which face generic competition and declining prescription volumes. The corresponding decline in royalty payments from $36.66 million to $28.08 million follows naturally from the sales decline at a constant royalty rate.
F. Contemporaneous Transfer Pricing Documentation
PPC maintained contemporaneous transfer pricing documentation for all four Tax Years at Issue. This documentation was prepared by Crestfield & Associates LLP, PPC's independent auditor and tax return preparer. The engagement partner for the transfer pricing documentation was Martin Ogilvy, CPA, and the transfer pricing partner was Susan Lam, CPA. Ms. Lam has over twenty years of experience in transfer pricing and has extensive expertise in pharmaceutical industry transfer pricing matters.
The contemporaneous documentation was prepared in compliance with the penalty-protection standards of IRC § 6662(e)(3)(B) and the applicable Treasury Regulations. The documentation established the economic analyses, methodologies, and comparable data supporting PPC's CSA cost-sharing ratios under Treasury Regulation § 1.482-7, the 4.5% royalty rate under Treasury Regulation § 1.482-4, and the arm's-length nature of the PCT payment.
The contemporaneous transfer pricing documentation was maintained in PPC's files and was produced to the IRS examination team in response to Information Document Request ("IDR") No. 4 on August 1, 2022, promptly upon request. PPC supplemented the documentation with additional analyses and data in response to subsequent IDRs as described below.
G. The IRS Examination
The IRS opened its examination of PPC's federal income tax returns for Tax Years 2017, 2018, 2019, and 2020 on May 16, 2022, as communicated by Letter 2205-A. The examination was conducted by the LB&I Northeast Transfer Pricing Practice under Examination Team ID LB&I-NE-TP-2022-00641.
The members of the IRS examination team relevant to this Protest are as follows:
• Supervisory Revenue Agent Gerald Meskill — Team Manager
• Revenue Agent Patricia Dunleavy — Lead Revenue Agent
• Dr. Alan Washburne — IRS Economist
• Franklin Rosario — Attorney-Advisor, IRS Office of Chief Counsel
• Donna Hirabayashi — Senior Counsel, IRS Office of Chief Counsel
Over the course of the examination, the IRS issued a total of 47 Information Document Requests ("IDRs") between June 2022 and September 2023. PPC cooperated fully with all IDRs, producing extensive documentation including, without limitation, the CSA Agreement, the Legacy IP License, contemporaneous transfer pricing documentation for all four tax years, board minutes and corporate governance records of PBI, financial statements of PPC and PBI, functional analyses, economic analyses, employee headcount data, organizational charts, product-level revenue data, regulatory filing records, and correspondence between PPC and PBI personnel. PPC also made available for interview twelve key PBI employees, including Managing Director Aidan Naughton, in response to IDR requests.
Despite PPC's full cooperation with the examination, the IRS issued its Notice of Proposed Adjustment ("NOPA") on October 12, 2023, proposing adjustments totaling $380,400,000 across the four Tax Years at Issue, plus a substantial valuation misstatement penalty under IRC § 6662(e). The IRS issued its 30-Day Letter on November 8, 2023, granting PPC the right to file this Protest.
H. Summary of Proposed Adjustments
The IRS proposes net adjustments totaling $380,400,000 across Tax Years 2017, 2018, 2019, and 2020. The proposed adjustments comprise three components:
1. CSA Cost-Sharing Ratio Adjustment: $235,010,000
The IRS proposes to increase PBI's cost-sharing percentage under the CSA by 8 to 12 percentage points per year, as set forth in the following table:
2. Royalty Rate Adjustment: $188,040,000
The IRS proposes to increase the legacy IP royalty rate from 4.5% to 11.0% of net sales, resulting in additional royalty income to PPC of 6.5% of net sales for each Tax Year at Issue:
3. Correlative Offset: ($42,650,000)
The IRS allowed a correlative offset of $42,650,000 to avoid double-counting between the CSA cost-sharing ratio adjustment and the royalty rate adjustment. The need for this correlative offset is itself significant, as it demonstrates the internal inconsistency of the IRS's overlapping adjustments and the imprecision of its approach. The gross proposed adjustments before the offset total $423,050,000 ($235,010,000 + $188,040,000), which exceeds the net adjustment of $380,400,000 by $42,650,000.
4. Total Net Proposed Adjustment: $380,400,000
In addition to the foregoing adjustments, the IRS asserted that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant, arguing that key Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions remained in the United States and were performed by PPC personnel. As discussed in detail in Section IV.D below, this assertion is contradicted by the extensive documentary evidence and testimony of PBI employees.
The IRS also relied on a PCT undervaluation assertion as background support for its proposed adjustments. Specifically, the IRS valued the PCT at $852,000,000, compared to PPC's actual PCT payment of $312,000,000 — a delta of $540,000,000. However, Tax Year 2012, in which the PCT payment was made, is not under examination. The IRS has instead used this PCT overvaluation assertion to support its recharacterization of the ongoing CSA cost-sharing ratios and royalty rates for Tax Years 2017–2020. As discussed in Section IV.C below, this approach is both legally and economically improper.
5. Proposed Penalty: IRC § 6662(e) Substantial Valuation Misstatement Penalty
The IRS proposes a 20% substantial valuation misstatement penalty under IRC § 6662(e) in the amount of approximately $15,977,000, computed as follows: $380,400,000 × 21% (weighted average effective tax rate) × 20% = approximately $15,977,000. The IRS reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h). PPC contests the proposed penalty in its entirety, as discussed in Section V below.
III. APPLICABLE LAW
A. IRC § 482 — Arm's-Length Standard
Section 482 of the Internal Revenue Code authorizes the Secretary of the Treasury, in any case of two or more organizations, trades, or businesses (whether or not incorporated, whether or not organized in the United States, and whether or not affiliated) owned or controlled directly or indirectly by the same interests, to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among such organizations, trades, or businesses, if the Secretary determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses.
The governing principle underlying IRC § 482 is the arm's-length standard. Treasury Regulation § 1.482-1(b)(1) provides that the purpose of section 482 is to place a controlled taxpayer on a tax parity with an uncontrolled taxpayer by determining the true taxable income of the controlled taxpayer. This standard requires that the results of a controlled transaction be consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances (the "arm's-length result"). See Treas. Reg. § 1.482-1(b)(1).
The arm's-length standard recognizes that the income generated by controlled transactions should approximate the income that would have been generated had the controlled transaction occurred between unrelated parties dealing at arm's length. The standard does not require mathematical precision but rather evaluates whether the pricing or other terms of a controlled transaction fall within the range of results that uncontrolled parties would have reached under comparable circumstances.
Treasury Regulation § 1.482-1(d) establishes the "best method rule," which provides that the arm's-length result of a controlled transaction must be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's-length result. There is no strict priority of methods; rather, the most reliable method is the method that produces the highest degree of comparability between the controlled transaction and uncontrolled comparables, and the highest quality of data and assumptions used in the analysis. The best method rule requires consideration of the degree of comparability between the controlled and uncontrolled transactions and the quality of the data and assumptions used in the analysis. See Treas. Reg. § 1.482-1(c) (providing guidance on comparability factors including functions performed, risks assumed, contractual terms, economic conditions, and property or services involved).
B. Treas. Reg. § 1.482-7 — Cost-Sharing Arrangements
Treasury Regulation § 1.482-7 sets forth detailed rules governing qualified cost-sharing arrangements ("QCSAs"). A QCSA is an arrangement between two or more controlled participants to share the costs and risks of developing intangible property in proportion to their reasonably anticipated benefits from the exploitation of that intangible property. See Treas. Reg. § 1.482-7(a).
Under Treasury Regulation § 1.482-7(b), a QCSA must meet the following requirements: (i) two or more controlled participants must join in the arrangement; (ii) each participant must have a reasonable expectation of deriving benefits from the cost-shared intangibles; (iii) each participant must bear a share of the intangible development costs ("Coss") that is consistent with its share of reasonably anticipated benefits ("RABs"); and (iv) the arrangement must be documented contemporaneously.
The concept of reasonably anticipated benefits is central to the QCSA framework. Treasury Regulation § 1.482-7(e) provides that each controlled participant's share of coss must be proportionate to its share of RABs from the exploitation of cost-shared intangibles. RABs are the benefits that the controlled participant reasonably anticipates that it will derive from the cost-shared intangibles. RABs are generally measured by reference to projected revenues, income, or other reasonably reliable measures that reflect the benefits each participant expects to receive from its exploitation of the cost-shared intangibles. The RAB shares must be determined on a basis that is consistent and reasonable across all participants.
When a controlled participant contributes pre-existing resources, capabilities, or rights to the CSA, a platform contribution transaction ("PCT") is required to compensate the other participants for the value contributed. Treasury Regulation § 1.482-7(g) provides that the arm's-length charge for a PCT must be determined using one of the specified methods, including (i) the income method, (ii) the acquisition price method, (iii) the market capitalization method, (iv) the residual profit split method, (v) the comparable uncontrolled transaction ("CUT") method, and (vi) the comparable profits method. The selection of the appropriate PCT valuation method is governed by the best method rule of Treasury Regulation § 1.482-1(d).
Treasury Regulation § 1.482-7(k) sets forth documentation requirements for QCSAs, requiring that the arrangement be documented in a written agreement and that the documentation address, among other things, the scope of the arrangement, the RAB shares, the cost-sharing methodology, and the terms of any PCT.
C. Treas. Reg. § 1.482-4 — Intangible Property
Treasury Regulation § 1.482-4 governs the determination of arm's-length consideration for transfers of intangible property. The regulation provides several methods for evaluating whether the consideration charged for a transfer of intangible property is arm's-length, including the comparable uncontrolled transaction ("CUT") method, the comparable profits method ("CPM"), and the profit split method.
The CUT method, set forth in Treasury Regulation § 1.482-4(c), evaluates whether the amount charged in a controlled transfer of intangible property is arm's-length by reference to the amount charged in comparable uncontrolled transactions. The CUT method requires a high degree of comparability between the controlled and uncontrolled transactions, including consideration of the following factors: (i) the terms of the transfer, including the territorial scope, exclusivity, duration, and other contractual terms; (ii) the comparability of the intangible property, including its nature, stage of development, and expected profitability; and (iii) the comparability of the economic conditions under which the controlled and uncontrolled transactions occurred. See Treas. Reg. § 1.482-4(c)(2).
Where the CUT method is applied, the reliability of the result depends on the degree of similarity between the controlled and uncontrolled transactions. Adjustments for material differences between the controlled and uncontrolled transactions may be necessary and appropriate, provided that such adjustments can be made with sufficient precision to yield reliable results. See Treas. Reg. § 1.482-4(c)(2)(ii).
D. IRC § 367(d) and Outbound Transfer of Intangibles
IRC § 367(d) provides that if a U.S. person transfers intangible property to a foreign corporation in certain transactions described in IRC § 332, 351, 354, 356, or 361, the transferor shall be treated as having sold such intangible property in exchange for payments contingent on the productivity, use, or disposition of the property. The provision is designed to ensure that U.S. taxpayers do not avoid U.S. tax on the value of intangible property by transferring it to a foreign corporation.
The interplay between IRC § 482 and IRC § 367(d) is relevant in the context of CSA structures because a CSA buy-in (i.e., a PCT payment) involves the acquisition by a foreign controlled participant of rights in pre-existing intangible property. However, a properly structured CSA under Treasury Regulation § 1.482-7 is not treated as an outbound transfer of intangible property subject to IRC § 367(d), provided that the CSA satisfies the requirements of the regulations and the PCT payment is arm's-length. See Treas. Reg. § 1.482-7(j)(3). The PPC-PBI CSA was structured and documented in compliance with Treasury Regulation § 1.482-7 and the PCT payment of $312,000,000 was arm's-length, as demonstrated in Section IV.C below. Accordingly, the CSA is properly treated as a QCSA and not as an outbound transfer of intangible property under IRC § 367(d).
E. OECD Transfer Pricing Guidelines as Persuasive Authority
The Organisation for Economic Co-operation and Development ("OECD") Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (the "OECD Guidelines") are widely recognized as persuasive authority in interpreting and applying the arm's-length standard. U.S. courts have looked to the OECD Guidelines as a useful reference in evaluating transfer pricing matters, although the Guidelines are not binding on U.S. taxpayers or the IRS. See, e.g., Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018) (referencing OECD Guidelines in analyzing transfer pricing methodologies).
The 2017 OECD Transfer Pricing Guidelines, as supplemented by the 2022 revisions, are particularly relevant to the issues in this Protest. Chapter VI of the OECD Guidelines addresses the transfer pricing of intangible property and introduces the DEMPE framework, which evaluates the allocation of intangible-related returns by reference to the functions of Development, Enhancement, Maintenance, Protection, and Exploitation of intangible property. Under the DEMPE framework, the entity that performs and controls the economically significant functions relating to intangibles, and that bears the risks associated with those functions, is entitled to the returns attributable to those functions.
Chapter VIII of the OECD Guidelines addresses cost contribution arrangements ("CCAs"), which are the OECD analog to the U.S. qualified cost-sharing arrangement. The OECD Guidelines recognize that a properly structured CCA allows participants to share the costs and risks of developing intangible property in proportion to their reasonably expected benefits, consistent with the arm's-length standard.
The DEMPE framework is relevant to this Protest because the IRS has asserted that PBI lacks sufficient economic substance and that key DEMPE functions remained in the United States. As discussed in Section IV.D below, PBI performed substantial DEMPE functions through its 185 employees, its Dublin-based management team, and its extensive regulatory, commercial, and operational activities across 68 country markets.
F. IRC § 6662(e) — Substantial Valuation Misstatement Penalty
IRC § 6662(a) imposes a 20% accuracy-related penalty on the portion of any underpayment of tax attributable to, among other things, a substantial valuation misstatement under chapter 1. For purposes of transfer pricing, IRC § 6662(e) provides that there is a substantial valuation misstatement if the net section 482 transfer pricing adjustment for any taxable year exceeds the lesser of $5,000,000 or 10% of the taxpayer's gross receipts.
However, IRC § 6662(e)(3)(B) provides an important exception: the penalty shall not apply with respect to any portion of an underpayment if the taxpayer demonstrates that (i) there was reasonable cause for the underpayment, and (ii) the taxpayer acted in good faith. In evaluating reasonable cause and good faith, the statute and regulations look to, among other things, whether the taxpayer maintained contemporaneous transfer pricing documentation that established a reasonable basis for the transfer pricing methodology employed and the amounts reported.
IRC § 6662(h) provides for an enhanced 40% penalty in the case of a "gross valuation misstatement," which applies when the net section 482 transfer pricing adjustment exceeds the lesser of $20,000,000 or 20% of the taxpayer's gross receipts. The IRS reserved but did not assert the gross valuation misstatement penalty in this case, a determination that implicitly acknowledges the weakness of the penalty position.
G. Key Case Law
Several judicial decisions are directly relevant to the transfer pricing issues raised in this Protest and support PPC's positions.
Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019), cert. denied, 141 S. Ct. 131 (2020), addressed the treatment of stock-based compensation costs in cost-sharing arrangements. The Ninth Circuit upheld the validity of Treasury Regulation § 1.482-7(d)(2), which requires the inclusion of stock-based compensation in the pool of intangible development costs shared under a CSA. While the holding in Altera is narrow in its specific application, the case affirms the general principle that the commensurate-with-income standard under IRC § 482(h) requires controlled transactions involving intangible property to yield results consistent with the income attributable to the intangible. PPC's CSA structure fully complies with the commensurate-with-income standard, as PBI's cost-sharing percentages are proportionate to its share of reasonably anticipated benefits measured by projected revenues.
Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018), involved the application of the CUT method in a pharmaceutical/medical device context. The Eighth Circuit reversed the Tax Court's determination that the IRS's comparable uncontrolled transactions were insufficiently comparable and remanded for further proceedings. The case underscores the importance of rigorous comparable selection and functional analysis in applying the CUT method. In particular, the court emphasized that comparables must be sufficiently similar to the controlled transaction in terms of the intangible property involved, the territorial scope, and the risk allocation. PPC's CUT analysis, prepared by Whitmore Valuation Group, satisfies these standards by identifying 14 comparable pharmaceutical license agreements with similar characteristics to the PPC-PBI Legacy IP License. The IRS's proposed CUT comparables, by contrast, involve materially different transactions and fail to meet the comparability requirements articulated in Harborview Corporation.
Hollowell & Co. v. Commissioner, 148 T.C. 108 (2017), aff'd, 934 F.3d 976 (9th Cir. 2019), addressed PCT valuation methodologies in the context of a CSA. The Tax Court rejected the IRS's valuation of the PCT buy-in payment, finding that the IRS's discount rate was unreasonably low and its revenue projections were overly optimistic. The court also rejected the IRS's application of the residual profit split method. The Hollowell & Co. decision is directly relevant to this Protest because the IRS has similarly used an unreasonably low discount rate (7.2% WACC) and overly optimistic revenue projections in its PCT valuation, as discussed in Section IV.C below.
Additional precedent supporting PPC's positions includes Tarrant Group v. Commissioner, 133 T.C. 297 (2009) (addressing buy-in payment valuation and rejecting the IRS's inflated valuations); and Xilinx, Inc. v. Commissioner, 598 F.3d 1191 (9th Cir. 2010) (addressing the arm's-length standard in the context of cost-sharing arrangements and the requirement that controlled transaction terms be consistent with terms that unrelated parties would have agreed to).
IV. ARGUMENT
A. PPC's Cost-Sharing Ratios Reflect Arm's-Length Allocations and Comply with Treas. Reg. § 1.482-7
1. PBI's Cost-Sharing Percentages Are Based on Reliable Reasonably Anticipated Benefit Projections. PBI's cost-sharing percentages for the Tax Years at Issue — 38.2% (2017), 39.6% (2018), 41.1% (2019), and 42.7% (2020) — were derived from contemporaneous projections of reasonably anticipated benefits, measured by projected revenue splits between the Americas and non-Americas territories, consistent with the requirements of Treasury Regulation § 1.482-7(e).
These projections were not arbitrary estimates or aspirational targets. Rather, they were based on detailed product-level revenue forecasts for each of PPC's key products — Veritaxol, Imvara, Cerulon, and pipeline compounds — prepared by PPC's and PBI's respective commercial teams with input from market research, historical sales trends, competitive intelligence, and market access data for each territory. The projections were reviewed and approved by PPC's and PBI's management and were incorporated into the cost-sharing calculations on a contemporaneous basis.
The reliability of these projections is confirmed by actual revenue realization data. As the following comparison demonstrates, actual non-Americas revenue shares were consistent with the projected shares used to calculate cost-sharing percentages:
• Veritaxol: Non-Americas net sales in 2020 were $1.34 billion, representing 43% of global net sales of $3.12 billion. This is consistent with the projected non-Americas share used in the cost-sharing calculation.
• Imvara: Non-Americas net sales in 2020 were $0.79 billion, representing 42% of global net sales of $1.87 billion. Again, this is consistent with the projected non-Americas share.
• Cerulon: Non-Americas net sales in 2020 were $0.28 billion, representing 45% of global net sales of $0.62 billion, consistent with projections.
The gradual increase in PBI's cost-sharing percentage from 38.2% in 2017 to 42.7% in 2020 reflects the growing non-Americas share of PPC's global product revenues over this period. This growth is directly attributable to PBI's commercial efforts in expanding market access, obtaining regulatory approvals, and building distribution capabilities in its territories. The increasing cost-sharing percentages thus reflect genuine economic developments — PBI's increasing share of reasonably anticipated benefits as its commercial capabilities matured — and are not an artifact of artificial transfer pricing manipulation.
Moreover, the methodology used to determine the cost-sharing percentages was applied consistently throughout the Tax Years at Issue and was documented contemporaneously in PPC's transfer pricing documentation. The methodology satisfies the requirements of Treasury Regulation § 1.482-7(e), which permits RABs to be measured by reference to projected revenues, income, or other reasonably reliable measures. PPC used projected revenue splits as the RAB measure, which is one of the most commonly used and widely accepted bases for RAB determinations in the transfer pricing context.
2. The IRS's Proposed Cost-Sharing Percentages Are Unsupported. The IRS proposes to increase PBI's cost-sharing percentages by 8 to 12 percentage points per year, from 38.2%–42.7% to 48.2%–53.7%. These proposed increases, which would result in aggregate additional cost-sharing payments of $235,010,000 over the four Tax Years at Issue, lack adequate economic foundation and are inconsistent with the arm's-length standard.
First, the IRS's position relies on the assertion that PPC's reasonably anticipated benefit projections understated the U.S.-source value of the intangible property developed under the CSA. However, the IRS has not identified any specific errors or biases in PPC's revenue projections. The projections were based on product-level data, prepared by the commercial teams closest to the relevant markets, and were validated by actual revenue realization data that closely tracked the projections. The IRS has offered no alternative projections based on independent market data or analyses; it has simply asserted, without supporting evidence, that the U.S. share of reasonably anticipated benefits should have been higher.
Second, and more fundamentally, the IRS's proposed cost-sharing percentages are driven primarily by its overvaluation of the PCT at $852 million, compared to PPC's actual PCT payment of $312 million. The IRS's logic appears to be that, because the pre-existing IP contributed by PPC to the CSA was more valuable than PBI's PCT payment reflected, PBI's ongoing cost-sharing percentages should be higher to compensate PPC for the alleged PCT undervaluation. This reasoning is both legally and economically flawed. The PCT and the ongoing cost-sharing percentages are separate transactions governed by separate provisions of Treasury Regulation § 1.482-7. The PCT compensates for the value of pre-existing IP at the time of the buy-in; the ongoing cost-sharing percentages allocate the costs of developing new intangible property going forward based on RABs. Even if the PCT were undervalued (which PPC disputes), the appropriate remedy would be an adjustment to the PCT itself, not an inflation of ongoing cost-sharing percentages. Moreover, Tax Year 2012 — the year in which the PCT payment was made — is not under examination.
Third, the magnitude of the IRS's proposed adjustments is unjustified. The proposed increases of 10.0, 11.0, 11.2, and 11.0 percentage points for Tax Years 2017 through 2020, respectively, would yield cost-sharing allocations that are far in excess of PBI's actual share of reasonably anticipated benefits. Under the IRS's proposed percentages, PBI would be paying for 48.2% to 53.7% of intangible development costs while deriving only 38.2% to 42.7% of the reasonably anticipated benefits, as measured by actual and projected revenue splits. This result is plainly inconsistent with the arm's-length standard, which requires that cost-sharing percentages be proportionate to RABs. No unrelated party would agree to bear intangible development costs that are disproportionately higher than its share of the benefits from the resulting intangible property.
3. CPM/TNMM Analysis Confirms PBI's Results Are Arm's-Length. In addition to the direct analysis of PBI's cost-sharing percentages described above, PPC has obtained an independent economic analysis that confirms the arm's-length nature of PBI's financial results under the CSA. This analysis was performed by Whitmore Valuation Group LLC, a nationally recognized independent transfer pricing and valuation firm, under the direction of Dr. Helena Vasquez, Managing Director, and Dr. Rohan Chakrabarti, Senior Director. Dr. Vasquez holds a Ph.D. in Economics from the Massachusetts Institute of Technology and has over twenty-five years of experience in transfer pricing, including extensive experience in pharmaceutical industry matters. Dr. Chakrabarti holds a Ph.D. in Economics from Columbia University and specializes in statistical and econometric methods applied to transfer pricing analyses.
Whitmore's analysis applied the comparable profits method ("CPM"), as described in Treasury Regulation § 1.482-5, and the analogous transactional net margin method ("TNMM") recognized by the OECD Guidelines. The analysis tested PBI's operating margins against those of a set of 22 comparable independent companies that perform functions and bear risks similar to those of PBI — specifically, independent pharmaceutical distributors and IP-holding companies that engage in regulatory, commercial, and supply-chain functions in connection with the commercialization of pharmaceutical products.
Whitmore's comparable set was selected through a rigorous screening process that identified companies with comparable functional profiles, risk characteristics, and industry classifications. Appropriate comparability adjustments were made to account for differences in working capital, geographic mix, and other factors that could affect the reliability of the comparison.
The results of the CPM/TNMM analysis demonstrate that PBI's operating margins fell within the interquartile range of the comparable set in all four Tax Years at Issue. This finding provides independent confirmation that PBI's reported financial results — which are a direct consequence of the CSA cost-sharing percentages at issue — are consistent with the results that would have been realized by an uncontrolled party performing similar functions, bearing similar risks, and using similar assets.
A summary of the economic analyses performed by Whitmore Valuation Group is attached hereto as Exhibit C (Summary of Economic Analyses).
B. PPC's 4.5% Royalty Rate Is Within the Arm's-Length Range
1. CUT Analysis Supports the 4.5% Rate. PPC's 4.5% royalty rate on the Legacy IP License is supported by a CUT analysis performed by Whitmore Valuation Group LLC. Whitmore identified a set of 14 comparable uncontrolled pharmaceutical license agreements through a comprehensive search of publicly available license agreement databases, SEC filings, and proprietary transaction databases. The search criteria were designed to identify license agreements involving pharmaceutical intellectual property of a nature, stage of development, territorial scope, and risk allocation similar to the PPC-PBI Legacy IP License.
The 14 comparable agreements involve licenses of pharmaceutical intellectual property for specific therapeutic indications in defined geographic territories. The licensed intellectual property in the comparable agreements consisted of mature, marketed pharmaceutical compounds — consistent with the legacy compounds licensed by PBI under the Legacy IP License — as opposed to early-stage, pre-clinical, or clinical-stage IP with materially different risk profiles. The comparable agreements involve territorial licenses for non-U.S. markets, similar to PBI's non-Americas territory. The risk allocations in the comparable agreements are consistent with the risk allocation under the PPC-PBI Legacy IP License, in which PBI bears commercialization risk, regulatory risk, pricing risk, and foreign exchange risk in its territory.
The interquartile range of royalty rates in the 14 comparable agreements is 3.1% to 6.8% of net sales, with a median royalty rate of 4.4%. PPC's 4.5% royalty rate falls squarely within this arm's-length range, near the median. Under Treasury Regulation § 1.482-1(e)(2)(iii)(B), if a controlled transaction falls within the interquartile range of comparable results, no adjustment is warranted. PPC's royalty rate of 4.5% is thus confirmed to be arm's-length by the most reliable method available — the CUT method applied using a robust set of comparable uncontrolled transactions.
The comparability analysis conducted by Whitmore evaluated each of the 14 comparable agreements against the comparability factors specified in Treasury Regulation § 1.482-4(c)(2), including the terms of the transfer (territorial scope, exclusivity, duration, sublicensing rights, termination provisions, and payment terms), the comparability of the intangible property (nature, stage of development, expected profitability, and competitive position), and the comparability of the economic conditions (market size, growth rates, competitive environment, and regulatory landscape). Whitmore concluded that all 14 agreements satisfy the comparability requirements to a degree sufficient to yield reliable results under the CUT method.
2. The IRS's Proposed 11.0% Rate Is Unsupported by Reliable Comparables. The IRS proposes to increase the legacy IP royalty rate from 4.5% to 11.0% of net sales, an increase of 6.5 percentage points that would result in aggregate additional royalty payments of $188,040,000 over the four Tax Years at Issue. This proposed adjustment is based on a CUT analysis prepared by IRS Economist Dr. Alan Washburne, which identified a different set of comparable license agreements that Dr. Washburne asserts support a royalty rate of 11.0%.
PPC respectfully submits that the IRS's proposed royalty rate of 11.0% is unsupported by reliable comparables and should be rejected for the following reasons:
First, Dr. Washburne's selected CUT comparables are materially different from the PPC-PBI Legacy IP License in several critical respects. The IRS's comparables involve earlier-stage intellectual property — in several cases, clinical-stage compounds that had not yet received marketing authorization — with substantially greater risk profiles than the mature, marketed legacy compounds licensed by PBI. Royalty rates for early-stage IP are typically higher than those for mature, marketed products because the licensor retains a greater share of the development risk and the licensee's expected returns are commensurately higher. Using early-stage comparables to benchmark a mature-product royalty rate violates the comparability requirements of Treasury Regulation § 1.482-4(c)(2).
Second, several of the IRS's comparables involve global or worldwide licenses, rather than territorial licenses for defined geographic markets. A worldwide license conveys broader rights and typically commands a higher royalty rate than a territorial license for a subset of markets. The PPC-PBI Legacy IP License is limited to non-Americas territories; using worldwide license agreements as comparables without appropriate adjustment for the narrower territorial scope introduces a systematic upward bias in the royalty rate comparison.
Third, certain of the IRS's comparables involve fundamentally different commercial terms — including milestone payments, equity components, co-development obligations, and exclusive manufacturing rights — that are not present in the PPC-PBI Legacy IP License. These terms affect the economic substance of the royalty rate and render direct comparison unreliable without material adjustments, which Dr. Washburne did not make.
Fourth, and most critically, the IRS's proposed rate of 11.0% falls well outside the interquartile range of 3.1% to 6.8% established by Whitmore's 14 reliable comparables. Under Treasury Regulation § 1.482-1(e)(2)(iii)(B), adjustments are warranted only when the controlled transaction falls outside the arm's-length range. PPC's royalty rate of 4.5% is within the arm's-length range. Even if one were to expand the range to include all 14 comparable data points (rather than the interquartile range), the IRS's proposed rate of 11.0% would remain an extreme outlier unsupported by the weight of the comparable data.
The aggregate proposed royalty adjustments of $188,040,000 across the four Tax Years at Issue — consisting of $52,950,000 for 2017, $49,550,000 for 2018, $44,970,000 for 2019, and $40,570,000 for 2020 — are thus without economic support and should be rejected.
3. Best Method Rule Supports CUT Method with PPC's Comparables. Under the best method rule of Treasury Regulation § 1.482-1(d), the CUT method applied using the 14 Whitmore-identified comparable agreements provides the most reliable measure of an arm's-length result for the legacy IP royalty rate. The CUT method is generally regarded as the most direct and reliable method for evaluating the arm's-length nature of a royalty rate, because it compares the controlled royalty directly to royalties observed in comparable uncontrolled transactions. See Treas. Reg. § 1.482-4(c)(1).
PPC's CUT analysis satisfies all comparability requirements under Treasury Regulation § 1.482-4(c)(2). The 14 comparable agreements involve pharmaceutical intellectual property of similar nature, stage of development, and expected profitability to the legacy compounds licensed under the PPC-PBI Legacy IP License. The territorial scope, exclusivity provisions, and risk allocations in the comparable agreements are sufficiently similar to those of the controlled transaction to yield reliable results. Appropriate adjustments were made to account for identified differences where necessary.
By contrast, the IRS's CUT analysis, based on Dr. Washburne's selected comparables, fails to satisfy the comparability requirements. The IRS's comparables involve materially different intangible property, different territorial scope, and different risk profiles. The IRS has not demonstrated that its CUT analysis provides a more reliable measure of an arm's-length result than PPC's analysis. Accordingly, PPC's CUT analysis should be accepted as the best method under Treasury Regulation § 1.482-1(d).
C. The PCT Payment of $312 Million Was Arm's-Length
1. Whitmore's Income Method / DCF Analysis Confirms $312M Within Range. In addition to the analyses described above, Whitmore Valuation Group LLC performed an independent valuation of the PCT payment using the income method / Discounted cash flow ("DCF") methodology. The income method is one of the specified methods for determining the arm's-length charge for a PCT under Treasury Regulation § 1.482-7(g), and is widely regarded as the most appropriate method for valuing buy-in payments involving pharmaceutical intellectual property.
Whitmore's DCF analysis projected the future cash flows attributable to the pre-existing intangible property contributed by PPC to the CSA, discounted to present value at the time of the PCT payment (July 1, 2012). The cash flow projections were based on contemporaneous product-level revenue and cost forecasts for the non-Americas territory, taking into account expected product lifecycle dynamics, competitive conditions, regulatory timelines, and probability-adjusted estimates of clinical and regulatory success for pipeline compounds.
Whitmore applied a weighted average cost of capital ("WACC") of 9.8% as the discount rate. This WACC was derived from an analysis of pharmaceutical industry cost of capital data, including equity risk premiums, beta comparables for specialty pharmaceutical companies, debt-to-equity ratios, and risk premiums reflecting the specific risk characteristics of PPC's product portfolio. The 9.8% WACC is consistent with the cost of capital observed for pharmaceutical companies of comparable size, risk profile, and product portfolio composition at the time of the PCT payment.
Based on this analysis, Whitmore concluded that the arm's-length range for the PCT payment was $278,000,000 to $361,000,000. The actual PCT payment of $312,000,000 falls comfortably within this range, near the midpoint. This conclusion confirms that the PCT payment was arm's-length and does not require adjustment.
2. The IRS's PCT Valuation at $852M Is Flawed. The IRS valued the PCT at $852,000,000, a delta of $540,000,000 from PPC's actual PCT payment of $312,000,000. PPC respectfully submits that the IRS's PCT valuation is materially flawed and unreliable for several reasons.
First, the IRS applied an unreasonably low discount rate of 7.2% WACC, compared to the 9.8% WACC supported by Whitmore's analysis. The 2.6 percentage point difference in discount rates has a dramatic impact on the present value of future cash flows, particularly over the long time horizons applicable to pharmaceutical IP valuation. The IRS's 7.2% WACC does not adequately reflect the risk profile o